Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine in Recurrent or Refractory Langerhans Cell Histiocytosis
NCT01796405Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of clofarabine in Langerhans cell histiocytosis (LCH), sponsored by Dana-Farber Cancer Institute. Status: withdrawn.
02
Drugs
clofarabine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT01796405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796405.